# Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

> **NCT04106362** · PHASE2 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- KRAS Protein Variant
- Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

## Interventions

- **BIOLOGICAL:** Cetuximab
- **DRUG:** Cisplatin
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT04106362
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-14
- **Primary completion:** 2023-05-23
- **Final completion:** 2023-05-23
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** low enrollment
- **Last updated:** 2023-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04106362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04106362, "Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04106362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*